Clinical analysis of 20 patients with non-Hodgkin lymphoma and autoimmune hemolytic anemia: A retrospective study
| Autor: | Mei-qing Wu, Ji-cheng Zhou, Zhen-jie Bai, Zheng-mian Peng, Wei-hua Zhao |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male medicine.medical_specialty Anemia diagnosis Chronic lymphocytic leukemia medicine.medical_treatment Biopsy Observational Study Gastroenterology 03 medical and health sciences 0302 clinical medicine immune system diseases Bone Marrow Internal medicine hemic and lymphatic diseases medicine Humans 030212 general & internal medicine neoplasms Survival analysis autoimmune hemolytic anemia Aged Retrospective Studies Aged 80 and over Chemotherapy treatment business.industry Incidence Lymphoma Non-Hodgkin non-Hodgkin lymphoma General Medicine lymphoma bone marrow infiltration Middle Aged medicine.disease Survival Analysis Lymphoma medicine.anatomical_structure 030220 oncology & carcinogenesis Mantle cell lymphoma Female Bone marrow Anemia Hemolytic Autoimmune Autoimmune hemolytic anemia business Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 |
| Popis: | Non-Hodgkin lymphoma (NHL) can co-exist with autoimmune hemolytic anemia (AIHA), a phenomenon known as AIHA-associated NHL (AIHA/NHL). However, few studies have reported AIHA/NHL incidence or its clinical characteristics. We conducted a retrospective analysis of 20 AIHA/NHL patients treated at our hospital from 2009 to 2018. AIHA/NHL was presented by only 0.91% of the NHL and 9.8% of the AIHA patients. In addition, AIHA occurred most frequently with angioimmunoblastic T-cell lymphoma (AITL) (7.31%), followed by marginal zone B-cell lymphoma (MZBL) (6.25%), B-cell lymphoma-unclassified (BCL-U) (4.25%), chronic lymphocytic leukemia/small lymphocyte lymphoma (CLL/SLL) (2.50%), and mantle cell lymphoma (MCL) (2.30%). In addition to the CLL/SLL patients with impaired bone marrow, 66.7% of the AIHA/NHL patients had lymphoma bone marrow infiltration (LBMI), of which 4 patients presented LBMI in bone marrow smears (BMS) but not in bone marrow biopsy (BMB) and 6 were positive for BMB but not BMS. The 1-, 3- and 5-year survival rates of AIHA/NHL patients were 70%, 30% and 20%, respectively, and they responded poorly to chemotherapy. In conclusion, AIHA can co-exist with various NHLs and the defining clinical characteristic of AIHA/NHL is the high incidence of LBMI. However, both BMS and BMB should be performed to avoid missed diagnosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|